



1644

\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. ANDERSON et al.

Group Art Unit: 1644

Application Serial No. 09/576,424

Examiner: Phillip Gambel

Filed: May 22, 2000

Title: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN
ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the listed references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after a first office action on the merits, but before a Final Action or Notice of Allowance. Please charge Deposit Account 03-3975 in the amount of \$180.00 in payment of the fee under 37 CFR § 1.17(p). Please credit or debit Deposit Account 03-3975 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

10/14/2004 HLE333 00000002 033975 09576424
01 FC:1806 180.00 DA

Respectfully Submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: October 13, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/CR/sm

Atty. Ref. No.
037003-0275681Client Ref.
1995-30-0233CP2**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/576,424

Filing Date: May 22, 2000

Examiner: Gambel, P.

Group Art Unit: 1644

Date: October 13, 2004

Page 1 of 4

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
	AR 4,816,397	03/1989	Boss
	BR 4,816,567	03/1989	Cabilly
	CR 5,116,964	05/1992	Capon
	DR 5,304,635	04/1994	Imam
	ER 5,434,131	07/1995	Linsley
	FR 5,885,579	03/1999	Linsley
	GR 6,162,432	12/2000	Wallner


FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	HR 0 171 496 B1	05/1993	EP	Taniguchi, et al.				
	IR 0 173 494 A2	03/1986	EP	Morrison, et al.				
	JR 0 239 400 B1	08/1994	EP	Winter, et al.				
	KR 0 194 276 A1	03/1986	EP	Neuberger, et al.				
	LR 0 451 216 B1	10/1991	EP	Queen				
	MR 0 555 880 A2, A3	08/1993	EP	Aruffo, et al.				
	NR 0 682 040 A1	11/1995	EP	Queen				
	OR 2 177 096 A	03/1986	GB	Neuberger, et al.				
	PR WO 92/06193	04/1992	WO	Gorman, et al.				
	QR WO 93/09812	05/1993	WO	Lederman, et al.				
	RR WO 94/28912	12/1994	WO	Thompson, et al.				
	SR WO 95/06481	03/1995	WO	Noelle, et al.				
	TR WO 95/06666	03/1995	WO	Noelle, et al.				
	UR WO 98/19706	05/1998	WO	Anderson, et al.				


OTHER (including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)


VR	Alegre M., et al., "Effect of single amino acid mutation on the activating and immunosuppressive properties of a "Humanized" OKT3 monoclonal antibody," J. Immunol., 1992, 148:3461-3468.
WR	Armitage R.J., et al., "Molecular and biological characterization of a murine ligand for CD40," Nature, 1992, 357:80-82.
XR	Azuma M., et al., "CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small Resting T Lymphocytes," J. Exp. Med., 1992, 175:353-360.
YR	Azuma M., et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes," J. Exp. Med., 1993, 177:845-850.
ZR	Azuma M.D., et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," Nature, 1993, 366:76-79.
AAR	Ben-Nun A., et al., "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," Eur J. Immunol., 1981, 11:195-199.
BBR	Blazar B.R., et al., "Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells," J Immunol., 1996, 157:3250-3259.
CCR	Boussiotis V.A., et al., "Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulate T-Cell activation," Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.

	DDR	Capon D.J., et al., "Designing CD4 immunoadhesins for AIDS therapy," Nature, 1989, 337, 525-531.
	EER	Cohen J., "New protein steals the show as 'costimulator' of T cells," Science, 1993, 262:844-845.
	FFR	Cohen J., "Mounting a targeted strike on unwanted immune responses," (news; comment), Science, 1992, 257:751.
	GGR	Dautigny A., et al., "Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid," FEBS Lett., 1985, 188(1):33-36.
	HHR	De Boer M., et al., "Functional Characterization of a Novel Anti-B7 Monoclonal Antibody," Eur. Journal of Immunology, 1992, 22:3071-3075.
	IIR	Delabie J., et al., "The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines," Blood, 1993, 82:2845-52.
	JJR	Dermer G.B., et al., "Another Anniversary for the war on cancer," Biotechnology, 1994, 12:320.
	KKR	Dillman R.O., et al., "Antibodies as cytotoxic therapy," 1994, J Clin Oncol., 12:1497-1515.
	LLR	Durie F.H., et al., "The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease," Research in Immunology, 1994, 145(3), 200-205 & 244-249.
	MMR	Durie F.H., et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," Science, 1993, 261:1328-1330.
	NNR	Engel et al, "The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen," Blood, 1994, 84, 1402-1407.
	OOR	Falini B., et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," The Lancet, 1992, 339:1195-1196.
	PPR	Freeman G.J., et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," Science, 1993, 262:907-909.
	QQR	Freeman G.J., et al., "CTLA-4 and CD28 MRNA are Coexpressed in Most T Cells After Activation," The Journal of Immunology, 1992, 149:3795-3801
	RRR	Freeman G.J., et al., "Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation," Science, 1993, 262:909-911.
	SSR	Geenen V. and G. Kroemer, "Multiple Ways to Cellular Immune Tolerance," Immunology Today, 1993, 14:573.
	TTR	Gerritse K., et al., "CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis," Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
	UUR	Gimmi C.D., et al., "Human T-Cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation," Proc. Natl. Acad. Sci., 1993, 90:6586-6590.
	VVR	Gottlieb A., et al., "Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis," J Invest Dermatol., 2000, 114:840, Abstract No. 546.
	WWR	Gottlieb A., et al., "Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody," J Am Acad Dermatol., 2002, 47:692-700.
	XXR	Gribben J.G., et al., "CTLA-4 mediates antigen specific apoptosis of human T cells." Proc. Natl. Acad. Sci. USA, 1995, 92:811-815.
	YYR	Grumet F.C., et al., "Soluble form of an HLA-B7 Class I Antigen Specifically Suppresses Humoral Alloimmunization." Human Immunology, 1995, 40:228-234.
	ZZR	Guinan E.C., et al., "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity," Blood, 1994, 84:3261-3282.
	AAAR	Hafler D.A., et al., "The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis," Ann. NY Acad. Sci., 1991, 636:251-265.
	BBBR	Harding F.A., et al., "CD28 Mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T Cell Clones." Nature, 1992, 356:607-609.
	CCCR	Hariharan K., et al., "Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma," Blood, 2001, 98(11 part 1):608a, Abstract No. 2549.
	DDDR	Hart D.N.J., et al., "B7/BB-1 is a Leucocyte Differentiation Antigen on Human Dendritic Cells Induced by Activation." Immunology, 1993, 79:616-620
	EEER	Hathcock K.S., et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science, 1993, 262:905-907.
	FFFR	Hollenbaugh D., et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," The EMBO J., 1992, 11(12):4313-4321.
	GGR	Ionescu-Tirgoviste, et al, "Correlations between insulin antibodies and the HLA system in a group of Type I diabetic patients in Bucharest," Med. Interre, 1986, 24(1), 11-17.



	HHHR	Janeway C.A., Jr. and K. Bottomly, "Signals and Signs for Lymphocyte Responses," Cell, 1994, 76:275-285.
	IIIR	Jenkins M.K., "The Role of Cell Division in the Induction of Clonal Anergy." Immunology Today, 1992, 13:69.
	JJJR	June C.H., et al., "The B7 and CD28 receptor families," Immunol Today, 1994, 15:321-331.
	KKKR	Kahan B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
	LLLR	Karpus, W.J., et al., "CD4+ suppressor cells differentially affect the production of IFN- γ by effector cells of experimental autoimmune encephalomyelitis," J. Immunol., 1989, 143:3492-3497.
	MMMR	Krummel M., et al., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," J. Exp. Med. 1995, 182:459-466.
	NNNR	Laman J., et al., "The role of gp39 (CD40 ligand) in EAE and MS," Journal of Neuroimmunology, 1994, 54(1-2):175, Abstract No. P01.06
	OOOR	LaSalle J.M., et al., "Early signaling defects in human T cells anergized by T cell presentation of autoantigen," J. Exp. Med., 1992, 176:177-186.
	PPPR	Lederman S., et al., "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help)," J. Exp. Med., 1992, 175:1091-1101.
	QQQR	Lenschow D.J., et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA-4Ig," Science, 1992, 257:789-795.
	RRRR	Lenschow D.J., et al., "Expression and Functional Significance of an Additional Ligand for CTLA-4," Proc. Natl. Acad. Sci., USA., 1993, 90:11054-11058.
	SSSR	Lider O., et al., "Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein," J. Immunol., 1989, 142:748-752.
	TTTR	Lin H., et al., "Long-term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA-4-Ig Plus Donor Specific Transfusion," J. Exp. Med., 1993, 178:1801.
	UUUR	Linsley, P.S. et al., "The role of the CD28 receptor during T cell responses to antigen," Annu Rev Immunol., 1993, 11:191-212.
	VVVR	Linsley, P.S., et al., "CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7," J. Exp. Med., 1991, 174:561.
	WWWR	Linsley P.S., et. al., "T-Cell Antigen CD28 Mediates Adhesion with B Cells by Interacting with Activation Antigen B7/BB-1." Proc. Natl. Acad. Sci., 1990, 87:5031-5035.
	XXXXR	Linsley, et al, "CD28 Engagement by B7/BB-1 Induces Transient Down-Regulation of CD28 Synthesis and Prolonged Unresponsiveness to CD28 Signaling," The Journal of Immunology, 1993, 150:3161-3169.
	YYYYR	Linsley, et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," J. Exp. Med., 1991, 173:721-730.
	ZZZR	Linsley P.S., et. al., "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes." J. Exp. Med., 1992, 176:1595-1604.
	AAAAR	Liu, et al., "Blockade of CD28/CTLA-4-B7 co-stimulatory pathway in colitic SCID mice," Gastroenterology, April 2000, Part 1 of 2, 118(4 Suppl 2):AGA-A575, Abstract No. 3000.
	BBBBR	McCafferty J., et al., "Phage antibodies: filamentous phage displaying antibody variable domains," Nature, 1990, 348:552-554.
	CCCCR	Miller A., et al., "Antigen-driven bystander suppression after oral administration of antigens," J. Exp. Med., 1991, 174:791-798.
	DDDDR	Mokhtarian F., et al., "Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice," Nature, 1984, 309:356-358.
	EEEEER	Morrison S., et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. U.S.A., 1984, 81:6851-6855.
	FFFFR	Morton P.A., et al., "Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)," J. Immunol., 1996, 156:1047-1054.
	GGGGR	Munro J.M., et al., "In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease," Blood, 1994, 83:793-798.
	HHHHR	Nestle F.O., et al, "Characterization of dermal dendritic cells in psoriasis," J. Clin. Invest., 1994, 94: 202-209.
	IIIIIR	Nickoloff B.J. et al., "T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28," Blood, 1994, 83(9):2580-2586.
	JJJJR	Noelle R.J., et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells," Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
	KKKKR	Olsson L., et al., "Human-human monoclonal antibody-producing hybridomas: technical aspects," Meth, Enzymol., 1983, 92:3-17.





LLLLR	Perrin P.J. et al., "Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis," J. Neuroimmunol., 1996, 65:31-39.
MMMMR	Pesoa S.A., et al., "Regulation of experimental allergic encephalomyelitis. Part 5. Role of the recipient in suppressor cell induction," J. Neuroimmunol, 1984, 7:131-135.
NNNNR	Pettinelli C.B., et al., "Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after <i>in vitro</i> activation of lymph node cells by myelin basic protein: requirement for Lyt 1 ⁺ 2 ⁻ T lymphocytes," J. Immunol., 1981, 127:1420-1423.
OOOR	Schwartz R.H., "Co-stimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," Cell, 1992, 71:1065-1068.
PPPPR	Schwartz R.H., "A cell culture model for T lymphocyte clonal anergy," Science, 1990, 248:1349-1356.
QQQQR	Selvakumar, A., et al., "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," Immunogenetics, 1992, 36:175-181
RRRRR	Sobel R.A., et al., "Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein," J. Neuropathol. Exp. Neurol., 1990, 49(5):468-479.
SSSSR	Stamenkovic I., et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," The EMBO J., 1989, 8(5),1403-1410.
TTTTTR	Suvas S., et al., "Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma," J Biol Chem., 2002, 277(10):7766-7775.
UUUUR	Takeda S., et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature, 1985, 314(4):452-454.
VVVVR	Tan P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," J. Exp. Med., 1993, 177:165-173.
WWWWR	Teng N. H. et al., "Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production," Proc. Natl. Acad. Sci. U.S.A., 1983, 80:7308-7312.
XXXXR	Tivol E.A., et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," Immunity, 1995, 3:541-547.
YYYYR	Turka L.A., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo," Proc. Natl. Acad. Sci., USA, 1992, 89:11102-11105.
ZZZZR	Toubert A., et al., "Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial out-membrane protein," Clin. Exp. Immunol., 1990, 82(1), 16-20.
AAAAAR	Toubert A., et al., "Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants," J. Immunol., 1988, 141(7), 2503-9.
BBBBBR	Tuohy V.K., et al., "Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice," J. Immunol., 1989, 142:1523-1527.
CCCCCR	Valle et al., "mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells," Immunol., 1990, 69(4), 531-535.
DDDDDR	Vandenberghe P., et al., "Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells," J. Exp. Med., 1992, 175:951-960.
EEEEER	van der Merwe, et al., "CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics," J. Exp. Med., 1997, 185: 393-403.
FFFFFR	Van der Veen R. C., et al., "The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein," J. Neuroimmunol., 1989, 21:183-191.
GGGGGR	Ward E.S., et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature, 1989, 341:544-546.
HHHHHR	Ward P.A., et al., "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," Ther Immunol., 1994, 1:165-171.
IIIIIR	Weyl D., et al., "Epitope mapping of human monoclonal antibodies to HLA-B27 by using natural and mutated antigenic variants," Hum. Immunol., 1991, 31(4), 271-276.
JJJJJR	Yi-qun Z. et al., Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens, Int Immunol., 1996, 8:37-44.
KKKKKR	Zavazava N., et al, "Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA," Transplantation, 1991, 51(4), 838-42.

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.